Lack of mutational hot spots during decitabine-mediated HIV-1 mutagenesis

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 11, 2015, Pages 6834-6843

  Rawson, Jonathan M O ^a   Landman, Sean R ^b   Reilly, Cavan S ^a,c   Bonnac, Laurent ^d   Patterson, Steven E ^a,d   Mansky, Louis M ^a,d  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DECITABINE; GUANINE; AZACITIDINE;

ARTICLE; CONTROLLED STUDY; HIGH THROUGHPUT SEQUENCING; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MUTAGENIC ACTIVITY; MUTATION RATE; NONHUMAN; PRIORITY JOURNAL; VIRUS MUTATION; VIRUS REPLICATION; ANALOGS AND DERIVATIVES; CELL LINE; DRUG EFFECTS; GENETICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MUTAGENESIS; MUTATION;

AZACITIDINE; CELL LINE; HIV INFECTIONS; HIV-1; HUMANS; MUTAGENESIS; MUTATION; MUTATION RATE;

EID: 84946226461     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01644-15     Document Type: Article

References (48)

1. Sanjuan R, Nebot MR, Chirico N, Mansky L.M., Belshaw R. 2010. Viral mutation rates. J Virol 84:9733-9748. http://dx.doi.org/10.1128/JVI.00694-10.
2. Biebricher CK, Eigen M. 2005. The error threshold. Virus Res 107:117-127. http://dx.doi.org/10.1016/j.virusres.2004.11.002.
3. Eigen M. 2002. Error catastrophe and antiviral strategy. Proc Natl Acad Sci U S A 99:13374-13376. http://dx.doi.org/10.1073/pnas.212514799.
4. Domingo E, Sheldon J, Perales C. 2012. Viral quasispecies evolution. Microbiol Mol Biol Rev 76:159-216. http://dx.doi.org/10.1128/MMBR.05023-11.
5. Loeb LA, Essigmann JM, Kazazi F, Zhang J., Rose KD, Mullins JI. 1999. Lethal mutagenesis of HIV with mutagenic nucleoside analogs. Proc Natl Acad Sci U S A 96:1492-1497. http://dx.doi.org/10.1073/pnas.96.4.1492.
6. Perales C, Martin V, Domingo E. 2011. Lethal mutagenesis of viruses. Curr Opin Virol 1:419-422. http://dx.doi.org/10.1016/j.coviro.2011.09.001.
7. Bonnac LF, Mansky LM, Patterson SE 2013. Structure-activity relationships and design of viral mutagens and application to lethal mutagenesis. J Med Chem 56:9403-9414. http://dx.doi.org/10.1021/jm400653j.
8. Asahina Y, Izumi N, Enomoto N., Uchihara M, Kurosaki M, Onuki Y., Nishimura Y, Ueda K, Tsuchiya K., Nakanishi H, Kitamura T, Miyake S. 2005. Mutagenic effects of ribavirin and response to interferon/ribavirin combination therapy in chronic hepatitis C. J Hepatol 43:623-629. http://dx.doi.org/10.1016/j.jhep.2005.05.032.
9. Chevaliez S, Brillet R, Lazaro E., Hezode C, Pawlotsky JM. 2007. Analysis of ribavirin mutagenicity in human hepatitis C virus infection. J Virol 81:7732-7741. http://dx.doi.org/10.1128/JVI.00382-07.
10. Cuevas JM, Gonzalez-Candelas F, Moya A., Sanjuan R. 2009. Effect of ribavirin on the mutation rate and spectrum of hepatitis C virus in vivo. J Virol 83:5760-5764. http://dx.doi.org/10.1128/JVI.00201-09.
11. Dietz J, Schelhorn SE, Fitting D, Mihm U., Susser S, Welker MW, Fuller C, Daumer M., Teuber G, Wedemeyer H, Berg T., Lengauer T, Zeuzem S, Herrmann E., Sarrazin C. 2013. Deep sequencing reveals mutagenic effects of ribavirin during monotherapy of hepatitis C virus genotype 1-infected patients. J Virol 87:6172-6181. http://dx.doi.org/10.1128/JVI.02778-12.
12. Harris KS, Brabant W, Styrchak S., Gall A, Daifuku R. 2005. KP-1212/1461, a nucleoside designed for the treatment of HIV byviral mutagenesis. Antiviral Res 67:1-9. http://dx.doi.org/10.1016/j.antiviral.2005.03.004.
13. Hicks C, Clay P, Redfield R., Lalezari J, Liporace R, Schneider S., Sension M, McRae M, Laurent JP 2013. Safety, tolerability, and efficacy of KP-1461 as monotherapy for 124 days in antiretroviral-experienced, HIV type 1-infected subjects. AIDS Res Hum Retroviruses 29:250-255.
14. Mullins JI, Heath L, Hughes J.P., Kicha J., Styrchak S, Wong KG, Rao U, Hansen A., Harris KS, Laurent JP, Li D, Simpson J.H., Essigmann JM, Loeb LA, Parkins J. 2011. Mutation of HIV-1 genomes in a clinical population treated with the mutagenic nucleoside KP1461. PLoS One 6:e15135. http://dx.doi.org/10.1371/journal.pone.0015135.
15. Furuta Y, Takahashi K, Fukuda Y., Kuno M, Kamiyama T, Kozaki K., Nomura N, Egawa H, Minami S., Watanabe Y, Narita H, Shiraki K. 2002. In vitro and in vivo activities of anti-influenza virus compound T-705. Antimicrob Agents Chemother 46:977-981. http://dx.doi.org/10.1128/AAC.46.4.977-981.2002.
16. Furuta Y, Gowen BB, Takahashi K, Shiraki K., Smee DF, Barnard DL. 2013. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Res 100:446-454. http://dx.doi.org/10.1016/j.antiviral.2013.09.015.
17. Arias A, Thorne L, Goodfellow I. 2014. Favipiravir elicits antiviral mutagenesis during virus replication in vivo. Elife 3:e03679.
18. Baranovich T, Wong SS, Armstrong J, Marjuki H., Webby RJ, Webster RG, Govorkova EA. 2013. T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro. J Virol 87:3741-3751. http://dx.doi.org/10.1128/JVI.02346-12.
19. Furuta Y, Takahashi K, Kuno-Maekawa M, Sangawa H., Uehara S, Kozaki K, Nomura N., Egawa H, Shiraki K. 2005. Mechanism of action of T-705 against influenza virus. Antimicrob Agents Chemother 49:981-986. http://dx.doi.org/10.1128/AAC.49.3.981-986.2005.
20. Jin Z, Smith LK, Rajwanshi V.K., Kim B., Deval J. 2013. The ambiguous base-pairing and high substrate efficiency of T-705 (favipiravir) ribofuranosyl 5'-triphosphate towards influenza A virus polymerase. PLoS One 8:e68347. http://dx.doi.org/10.1371/journal.pone.0068347.
21. Sangawa H, Komeno T, Nishikawa H., Yoshida A, Takahashi K, Nomura N., Furuta Y. 2013. Mechanism of action of T-705 ribosyl triphosphate against influenza virus RNA polymerase. Antimicrob Agents Chemother 57:5202-5208. http://dx.doi.org/10.1128/AAC.00649-13.
22. Clouser CL, Patterson SE, Mansky LM 2010. Exploiting drug repositioning for discovery of a novel HIV combination therapy. J Virol 84: 9301-9309. http://dx.doi.org/10.1128/JVI.01006-10.
23. Dapp MJ, Clouser CL, Patterson S, Mansky LM 2009. 5-Azacytidine can induce lethal mutagenesis in human immunodeficiency virus type 1. J Virol 83:11950-11958. http://dx.doi.org/10.1128/JVI.01406-09.
24. Desimmie BA, Delviks-Frankenberrry KA, Burdick R.C., Qi D., Izumi T, Pathak VK. 2014. Multiple APOBEC3 restriction factors for HIV-1 and one Vif to rule them all. J Mol Biol 426:1220-1245. http://dx.doi.org/10.1016/j.jmb.2013.10.033.
25. Refsland EW, Harris RS 2013. The APOBEC3 family of retroelement restriction factors. Curr Top Microbiol Immunol 371:1-27.
26. Nathans R, Cao H, Sharova N., Ali A, Sharkey M, Stranska R., Stevenson M, Rana TM. 2008. Small-molecule inhibition of HIV-1 Vif. Nat Biotechnol 26:1187-1192. http://dx.doi.org/10.1038/nbt.1496.
27. Zuo T, Liu D, Lv W., Wang X, Wang J, Lv M., Huang W, Wu J, Zhang H., Jin H, Zhang L, Kong W., Yu X. 2012. Small-molecule inhibition of human immunodeficiency virus type 1 replication by targeting the interaction between Vif and Elongin C. J Virol 86:5497-5507. http://dx.doi.org/10.1128/JVI.06957-11.
28. Matsui M, Shindo K, Izumi T., Io K, Shinohara M, Komano J., Kobayashi M, Kadowaki N, Harris R.S., Takaori-Kondo A. 2014. Small molecules that inhibit Vif-induced degradation of APOBEC3G. Virol J 11:122. http://dx.doi.org/10.1186/1743-422X-11-122.
29. Pery E, Sheehy A, Nebane N.M., Brazier AJ, Misra V, Rajendran KS, Buhrlage S.J., Mankowski MK, Rasmussen L, White EL, Ptak R.G., Gabuzda D. 2015. Identification of a novel HIV-1 inhibitor targeting Vif-dependent degradation of human APOBEC3G protein. J Biol Chem 290:10504-10517. http://dx.doi.org/10.1074/jbc.M114.626903.
30. Clouser CL, Chauhan J, Bess M.A., van Oploo JL, Zhou D, Dimick-Gray S, Mansky LM, Patterson SE 2012. Anti-HIV-1 activity of resveratrol derivatives and synergistic inhibition of HIV-1 by the combination of resveratrol and decitabine. Bioorg Med Chem Lett 22:6642-6646. http://dx.doi.org/10.1016/j.bmcl.2012.08.108.
31. Clouser CL, Holtz CM, Mullett M, Crankshaw D.L., Briggs JE, O'Sullivan MG, Patterson SE, Mansky LM 2012. Activity of a novel combined antiretroviral therapy of gemcitabine and decitabinein a mouse model for HIV-1. Antimicrob Agents Chemother 56:1942-1948. http://dx.doi.org/10.1128/AAC.06161-11.
32. Clouser CL, Bonnac L, Mansky L.M., Patterson SE. 2014. Characterization of permeability, stability and anti-HIV-1 activity of decitabine and gemcitabine divalerate prodrugs. Antivir Chem Chemother 23:223-230. http://dx.doi.org/10.3851/IMP2682.
33. Rawson JM, Landman SR, Reilly C.S., Mansky LM. 2015. HIV-1 and HIV-2 exhibit similar mutation frequencies and spectra in the absence of G-to-A hypermutation. Retrovirology 12:60. http://dx.doi.org/10.1186/s12977-015-0180-6.
34. McKenna A, Hanna M, Banks E., Sivachenko A, Cibulskis K, Kernytsky A., Garimella K, Altshuler D, Gabriel S., Daly M, DePristo MA. 2010. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res 20:1297-1303. http://dx.doi.org/10.1101/gr.107524.110.
35. Wolfinger R, O'Connell M. 1993. Generalized linear mixed models: a pseudo-likelihood approach. J Stat Comput Simul 48:233-243. http://dx.doi.org/10.1080/00949659308811554.
36. Jackson-Grusby L., Laird PW, Magge S.N., Moeller BJ, Jaenisch R. 1997. Mutagenicity of 5-aza-2'-deoxycytidine is mediated by the mammalian DNA methyltransferase. Proc Natl Acad Sci U S A 94:4681-4685. http://dx.doi.org/10.1073/pnas.94.9.4681.
37. Lin KT, Momparler RL, Rivard GE 1981. High-performance liquid chromatographic analysis of chemical stability of 5-aza-2'-deoxycytidine. J Pharm Sci 70:1228-1232. http://dx.doi.org/10.1002/jps.2600701112.
38. Liu Z, Marcucci G, Byrd J.C., Grever M., Xiao J, Chan KK. 2006. Characterization of decomposition products and preclinical and low dose clinical pharmacokinetics ofdecitabine (5-aza-2'-deoxycytidine)byanew liquid chromatography/tandem mass spectrometry quantification method. Rapid Commun Mass Spectrom 20:1117-1126. http://dx.doi.org/10.1002/rcm.2423.
39. Rogstad DK, Herring JL, Theruvathu J.A., Burdzy A., Perry CC, Neidigh JW, Sowers LC. 2009. Chemical decomposition of 5-aza-2'-deoxycytidine (decitabine): kinetic analyses and identification ofproducts by NMR, HPLC, and mass spectrometry. Chem Res Toxicol 22:1194-1204. http://dx.doi.org/10.1021/tx900131u.
40. Lamparska K, Clark J, Babilonia G., Bedell V, Yip W, Smith SS 2012. 2'-Deoxyriboguanylurea, the primary breakdown product of 5-aza-2'-deoxyribocytidine, is a mutagen, an epimutagen, an inhibitor of DNA methyltransferases and an inducer of 5-azacytidine-type fragile sites. Nucleic Acids Res 40:9788-9801. http://dx.doi.org/10.1093/nar/gks706.
41. Quintas-Cardama A., Santos FP, Garcia-Manero G. 2010. Therapy with azanucleosides for myelodysplastic syndromes. Nat Rev Clin Oncol 7:433-444. http://dx.doi.org/10.1038/nrclinonc.2010.87.
42. Oz S, Raddatz G, Rius M., Blagitko-Dorfs N, Lubbert M, Maercker C., Lyko F. 2014. Quantitative determination of decitabine incorporation into DNA and its effect on mutation rates in human cancer cells. Nucleic Acids Res 42:e152. http://dx.doi.org/10.1093/nar/gku775.
43. Maslov AY, Lee M, Gundry M., Gravina S, Strogonova N, Tazearslan C., Bendebury A, Suh Y, Vijg J. 2012. 5-Aza-2'-deoxycytidine-induced genome rearrangements are mediated by DNMT1. Oncogene 31:5172-5179. http://dx.doi.org/10.1038/onc.2012.9.
44. Mansky LM, Temin HM 1995. Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J Virol 69:5087-5094.
45. Mansky LM. 1996. Forward mutation rate of human immunodeficiency virus type 1 in a Tlymphoid cell line. AIDS Res Hum Retroviruses 12:307-314. http://dx.doi.org/10.1089/aid.1996.12.307.
46. Abram ME, Ferris AL, Shao W, Alvord W.G., Hughes SH. 2010. Nature, position, and frequency of mutations made in a single cycle of HIV-1 replication. J Virol 84:9864-9878. http://dx.doi.org/10.1128/JVI.00915-10.
47. Suspene R, Rusniok C, Vartanian J.P., Wain-Hobson S. 2006. Twin gradients in APOBEC3 edited HIV-1 DNA reflect the dynamics of lentiviral replication. Nucleic Acids Res 34:4677-4684. http://dx.doi.org/10.1093/nar/gkl555.
48. Yu Q, Konig R, Pillai S., Chiles K, Kearney M, Palmer S., Richman D, Coffin JM, Landau NR 2004. Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome. Nat Struct Mol Biol 11:435-442. http://dx.doi.org/10.1038/nsmb758.